Coherus BioSciences Announces New Employment Inducement Grants
November 27 2018 - 6:00PM
Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that
effective November 14, 2018, the compensation committee of the
company’s board of directors granted 5 new employees options to
purchase an aggregate of 60,000 shares of the company’s common
stock with a per share exercise price of $10.96, the closing
trading price on the grant date. The stock options were
granted pursuant to the Coherus BioSciences, Inc. 2016 Employment
Commencement Incentive Plan, which was approved by the company’s
board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq
Global Select Market for equity grants to induce new employees to
enter into employment with the company.
About Coherus BioSciences, Inc.Coherus is a
leading biosimilar company that develops and commercializes
high-quality therapeutics for major regulated markets. Biosimilars
are intended for use in place of existing, branded biologics to
treat a range of chronic and often life-threatening diseases, with
the potential to reduce costs and expand patient access. Composed
of a team of proven industry veterans with world-class expertise in
process science, analytical characterization, protein production,
sales and marketing and clinical-regulatory development, Coherus is
positioned as a leader in the global biosimilar marketplace.
Coherus has received regulatory approval for UDENYCA™
(pegfilgrastim-cbqv) in the U.S. and European Union and is
advancing two late-stage clinical products towards
commercialization, CHS-1420 (adalimumab biosimilar) and CHS-0214
(etanercept biosimilar), and developing a robust pipeline of future
products in ophthalmology (including CHS-3351, a ranibizumab
biosimilar, and CHS-2020, an aflibercept biosimilar), as well as
CHS-131, a small molecule for nonalcoholic steatohepatitis (NASH)
and multiple sclerosis. For additional information, please
visit www.coherus.com.
CONTACT:
David S. ArringtonVP, Investor Relations & Corporate
AffairsCoherus BioSciences, Inc.darrington@coherus.com+1 (650)
395-0196
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024